Novel compound PS-101 exhibits selective inhibition in non-small-cell lung cancer cell by blocking the EGFR-driven antiapoptotic pathway

Biochemical Pharmacology

Volumn 86, Issue 12, 2013, Pages 1721-1730

  Zhang, Guo Hai ^a   Cai, Le Jing ^a   Wang, Yan Fei ^a   Zhou, Yuan Hua ^a   An, Yun Feng ^a   Liu, Yan Cheng ^a   Peng, Yan ^a   Chen, Zhen Feng ^a   Liang, Hong ^a  

^a GUANGXI NORMAL UNIVERSITY   (China)

Author keywords

Antiapoptotic pathway; EGFR; Inhibition selectivity; Non small cell lung cancer; PS 101

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; PLUMBAGIN; PROTEIN BAD; PROTEIN BCL 2; PS 101; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; AMINOSUGAR; EPIDERMAL GROWTH FACTOR RECEPTOR; NAPHTHOQUINONE; PRIMER DNA; PS-101;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL DEATH; CELL PROLIFERATION; CELL SIZE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG SYNTHESIS; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CANCER; LIVER CELL; LUNG FIBROBLAST; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE; SCREENING; STOMACH CANCER; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

AMINO SUGARS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; DNA PRIMERS; DOWN-REGULATION; HUMANS; LUNG NEOPLASMS; NAPHTHOQUINONES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION, GENETIC;

EID: 84888881885     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.10.013     Document Type: Article

References (34)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
3. T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, and J. Tsurutani Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
4. R. Rosell, G. Robinet, A. Szczesna, R. Ramlau, M. Constenla, and B.C. Mennecier Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer Ann Oncol 19 2008 362 369 (Pubitemid 351201721)
5. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, and A. Dowlati Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
6. J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
7. R. Sordella, D.W. Bell, D.A. Haber, and J. Settleman Gefitinib- sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167 (Pubitemid 39100331)
8. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, and R.A. Okimoto Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
9. C.C. Lin, F.A. Melo, R. Ghosh, K.M. Suen, L.J. Stagg, and J. Kirkpatrick Inhibition of basal FGF receptor signaling by dimeric Grb2 Cell 149 2012 1514 1524
10. K.S. Nguyen, S. Kobayashi, and D.B. Costa Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway Clin Lung Cancer 10 2009 281 289
11. S. Sinha, K. Pal, A. Elkhanany, S. Dutta, Y. Cao, and G. Mondal Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo Int J Cancer 132 2013 1201 1212
12. J. Li, L. Shen, F.R. Lu, Y. Qin, R. Chen, and J. Li Plumbagin inhibits cell growth and potentiates apoptosis in human gastric cancer cells in vitro through the NF-kappaB signaling pathway Acta Pharmacol Sin 33 2012 242 249
13. J.M. Sand, B. Bin Hafeez, M.S. Jamal, O. Witkowsky, E.M. Siebers, and J. Fischer Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas Carcinogenesis 33 2012 184 190
14. K.A. Manu, M.K. Shanmugam, P. Rajendran, F. Li, L. Ramachandran, and H.S. Hay Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4 Mol Cancer 10 2011 107 120
15. S. Padhye, P. Dandawate, M. Yusufi, A. Ahmad, and F.H. Sarkar Perspectives on medicinal properties of plumbagin and its analogs Med Res Rev 32 2012 1131 1158
16. L. Lai, J. Liu, D. Zhai, Q. Lin, L. He, and Y. Dong Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2 Br J Pharmacol 165 2012 1084 1096
17. J.R. Jiang, S. Yuan, J.F. Ding, S.C. Zhu, H.D. Xu, and T. Chen Conversion of puerarin into its 7-O-glycoside derivatives by Microbacterium oxydans (CGMCC 1788) to improve its water solubility and pharmacokinetic properties Appl Microbiol Biotechnol 81 2008 647 657
18. M.J. Chung, N.J. Sung, C.S. Park, D.K. Kweon, A. Mantovani, and T.W. Moon Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57 BL/6J mice Eur J Pharmacol 578 2008 159 170 (Pubitemid 350309595)
19. C.E. Rüfer, A. Bub, J. Möseneder, P. Winterhalter, M. Stürtz, and S.E. Kulling Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study Am J Clin Nutr 87 2008 1314 1323 (Pubitemid 351679773)
20. N.N. Danial, and S.J. Korsmeyer Cell death: critical control points Cell 116 2004 205 219 (Pubitemid 38167313)
21. H. Zou, Y. Li, X. Liu, and X. Wang An APAF-1. Cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9 J Biol Chem 274 1999 11549 11556
22. M. Certo, V. Del Gaizo Moore, M. Nishino, G. Wei, S. Korsmeyer, and S.A. Armstrong Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members Cancer Cell 9 2006 351 365 (Pubitemid 43668734)
23. M.C. Wei, W.X. Zong, E.H. Cheng, T. Lindsten, V. Panoutsakopoulou, and A.J. Ross Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death Science 292 2001 727 730 (Pubitemid 32385543)
24. L. Chen, S.N. Willis, A. Wei, B.J. Smith, J.I. Fletcher, and M.G. Hinds Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function Mol Cell 17 2005 393 403 (Pubitemid 40193310)
25. D.J. Silva, H. Wang, N.M. Allanson, R.K. Jain, and M.J. Sofia Stereospecific solution- and solid-phase glycosylations. Synthesis of β-linked saccharides and construction of disaccharide libraries using phenylsulfenyl 2-deoxy-2-trifluoroacetamido glycopyranosides as glycosyl donors J Org Chem 64 1999 5926 5929
26. M.L. Bowen, Z.-F. Chen, A.M. Roos, R. Misri, U. Hafeli, and M.J. Adam Long-chain rhenium and technetium glucosamine conjugates Dalton Trans 42 2009 9228 9236
27. L. Salmon-Chemin, E. Buisine, V. Yardley, S. Kohler, M.-A. Debreu, and V. Landry 2- and 3-Substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity J Med Chem 44 2001 548 565 (Pubitemid 32156097)
28. K. Yu, C. Shi, L. Toral-Barza, J. Lucas, B. Shor, and J.E. Kim Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2 Cancer Res 70 2010 621 631
29. W. Luo, J. Li, D. Zhang, T. Cai, L. Song, and X.M. Yin Bid mediates anti-apoptotic COX-2 induction through the IKKbeta/NFkappaB pathway due to 5-MCDE exposure Curr Cancer Drug Targets 10 2010 96 106
30. L. Cheng, R.E. Alexander, G.T. Maclennan, O.W. Cummings, R. Montironi, and A. Lopez-Beltran Molecular pathology of lung cancer: key to personalized medicine Mod Pathol 25 2012 347 369
31. J. Cronin, E. McAdam, A. Danikas, C. Tselepis, P. Griffiths, and J. Baxter Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE) Am J Gastroenterol 106 2011 46 56
32. G. Zhang, Q. Wang, and R. Xu Therapeutics based on microRNA: a new approach for liver cancer Curr Genomics 11 2010 311 325
33. R. Rani, V.K. Kansal, D. Kaushal, and S. De Dietary intervention of cow ghee and soybean oil on expression of cell cycle and apoptosis related genes in normal and carcinogen treated rat mammary gland Mol Biol Rep 38 2011 3299 3307
34. S.Y. Wong Apoptosis in cancer: from pathogenesis to treatment J Exp Clin Cancer Res 30 2011 87 100